Methods for BPH treatment
Benign prostatic hyperplasia (BPH) is the most common disease of older men. The first signs of BPH were found in 8% of men aged 31 to 40 years. Men older than ’61 are 70% affected by BPH or more, and after 80 years – 90%. Almost all men in their lifetime develop microscopic BPH, 50% – the macroscopic. In industrialized countries, surgery for BPH is the second largest volume of all surgical operations, second only to surgical removal of cataracts. According to the UN population over the age of 60 years by the end of the twentieth century has increased in comparison with its midpoint by more than 3 times. Given the tendency of the aging of the world population, we can assume an increase in the relevance of the problem of diagnosis and treatment of BPH.
The variety of treatments for BPH indicates that none of them is perfect and requires the determination of their place in the structure of the treatment. The same for all treatments relative indication is the presence of clinically benign prostatic hyperplasia.
At present, one of the main factors in the development of BPH recognized imbalance between testosterone and its more active derivative – dihydrotestosterone (DHT), the form in which it operates and after the differentiation of the structures of the male urogenital tract.
Herbal drugs are presented, mainly extracts lipidosterolic nature of American sago palm (Serenoa repens) and wild plum Cameroon (Pygeum africanum). The mechanism of action of their insufficiently studied. Presumably, the therapeutic effect of the application of these drugs caused by anti-inflammatory action due to inhibition of the synthesis of prostaglandins, cytotoxic effects on cells hyperplasia, and effects on tissue growth factors.
The introduction of the methods of conservative treatment led to a review of the indications for surgical treatment in the early stages of the disease. This makes the doctor slowly titrating, to select effective and safe dose. Less affect on blood pressure shows tamsulosin, a selective antagonist of α-AR, acting on a subtype 1A. This species, making up 70% of the α1-AR is localized mainly in the prostate. Perhaps these receptors play the most important role in the development of a dynamic component IVO.
Comments are currently closed.